AR076655A1 - Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b - Google Patents
Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3bInfo
- Publication number
- AR076655A1 AR076655A1 ARP100101527A ARP100101527A AR076655A1 AR 076655 A1 AR076655 A1 AR 076655A1 AR P100101527 A ARP100101527 A AR P100101527A AR P100101527 A ARP100101527 A AR P100101527A AR 076655 A1 AR076655 A1 AR 076655A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- compositions
- methods
- going
- complement protein
- Prior art date
Links
- 102000000989 Complement System Proteins Human genes 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 108010069112 Complement System Proteins Proteins 0.000 title 1
- 108010078015 Complement C3b Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17586009P | 2009-05-06 | 2009-05-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076655A1 true AR076655A1 (es) | 2011-06-29 |
Family
ID=43063291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101527A AR076655A1 (es) | 2009-05-06 | 2010-05-05 | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20100291106A1 (enExample) |
| EP (1) | EP2427491A2 (enExample) |
| JP (1) | JP2012525829A (enExample) |
| KR (1) | KR20120088551A (enExample) |
| CN (1) | CN102459334A (enExample) |
| AR (1) | AR076655A1 (enExample) |
| AU (1) | AU2010252156A1 (enExample) |
| CA (1) | CA2760757A1 (enExample) |
| CL (1) | CL2011002756A1 (enExample) |
| CO (1) | CO6440515A2 (enExample) |
| EA (1) | EA201101593A1 (enExample) |
| EC (1) | ECSP11011445A (enExample) |
| IL (1) | IL216061A0 (enExample) |
| MA (1) | MA33402B1 (enExample) |
| MX (1) | MX2011011754A (enExample) |
| PE (1) | PE20120899A1 (enExample) |
| SG (1) | SG175432A1 (enExample) |
| TN (1) | TN2011000528A1 (enExample) |
| TW (1) | TW201043638A (enExample) |
| UY (1) | UY32612A (enExample) |
| WO (1) | WO2010136311A2 (enExample) |
| ZA (1) | ZA201107551B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0510485A (pt) | 2004-04-30 | 2007-11-13 | Allergan Inc | implantes inibidores de tirosina cinase intravìtreos biodegradáveis |
| SI2044111T1 (sl) | 2006-06-21 | 2015-02-27 | Musc Foundation For Research Development | Ciljanje komplementa faktorja H za zdravljenje bolezni |
| RS20120461A1 (sr) | 2009-07-02 | 2013-06-28 | Musc Foundation For Research Development | Metode za stimulaciju regeneracije jetre |
| NZ600393A (en) | 2009-11-05 | 2014-08-29 | Alexion Cambridge Corp | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| TR201904224T4 (tr) | 2010-05-14 | 2019-05-21 | Univ Colorado Regents | Geliştirilmiş kompleman reseptör 2 (CR2) hedefleme grupları. |
| CN103249432A (zh) | 2010-06-22 | 2013-08-14 | 科罗拉多大学董事会,法人团体 | 补体成分3的C3d片段的抗体 |
| EP2646821A4 (en) * | 2010-11-29 | 2015-09-23 | Novelmed Therapeutics Inc | NEOANTIC BODY FOR THE DIAGNOSIS OF TISSUE INJURY |
| US9243060B2 (en) | 2012-04-03 | 2016-01-26 | Novelmed Therapeutics, Inc. | Humanized anti-factor C3b antibodies and uses thereof |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| WO2014028865A1 (en) | 2012-08-17 | 2014-02-20 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
| EP4613778A3 (en) | 2012-10-25 | 2025-12-17 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
| PL2914291T3 (pl) | 2012-11-02 | 2022-10-03 | Bioverativ Usa Inc. | Przeciwciała anty-C1s dopełniacza i ich zastosowania |
| WO2014085527A1 (en) | 2012-11-29 | 2014-06-05 | Bayer Healthcare Llc | Humanized monoclonal antibodies against activated protein c and uses thereof |
| JP6505079B2 (ja) | 2013-03-29 | 2019-04-24 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法 |
| JP6211701B2 (ja) | 2013-08-07 | 2017-10-11 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 非典型溶血性尿毒症症候群のバイオマーカータンパク質 |
| EP3054965B1 (en) * | 2013-10-07 | 2021-04-14 | Massachusetts Eye & Ear Infirmary | Anti-factor d antibody for use in preventing or reducing retinal detachment |
| WO2015099838A2 (en) * | 2013-12-24 | 2015-07-02 | Novelmed Therapeutics, Inc. | Compositions and methods of treating ocular diseases |
| KR20160126054A (ko) | 2014-02-27 | 2016-11-01 | 알러간, 인코포레이티드 | 보체 인자 Bb 항체 |
| US11077187B2 (en) | 2015-11-17 | 2021-08-03 | Oklahoma Medical Research Foundation | Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof |
| US20200048332A1 (en) | 2016-10-12 | 2020-02-13 | Bioverativ Usa Inc. | Anti-c1s antibodies and methods of use thereof |
| EP3526248A4 (en) | 2016-10-17 | 2020-07-08 | Musc Foundation for Research Development | COMPOSITIONS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DAMAGE |
| US11136381B2 (en) | 2018-04-03 | 2021-10-05 | Ngm Biopharmaceuticals, Inc. | Anti-C3 antibodies |
| EP4257602A3 (en) | 2018-06-11 | 2023-12-27 | Aarhus Universitet | Single domain antibodies for complement regulation |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| CA3214281A1 (en) * | 2021-03-19 | 2022-09-22 | Elpis Biopharmaceuticals | Antibodies specific to sialic acid-binding ig-like lectin 15 and uses thereof |
| WO2024108529A1 (en) * | 2022-11-25 | 2024-05-30 | Linno Pharmaceuticals Inc. | Properdin binding protein and use thereof |
| EP4453028A1 (en) | 2021-12-22 | 2024-10-30 | CDR-Life AG | Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases |
| KR20230105972A (ko) | 2022-01-05 | 2023-07-12 | 주식회사 카나프테라퓨틱스 | 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도 |
| CN114874329A (zh) * | 2022-05-19 | 2022-08-09 | 江苏大学 | 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用 |
| AU2023347940A1 (en) * | 2022-09-20 | 2025-03-27 | Visterra, Inc. | Treatment of complement mediated diseases and disorders with c3b-antibodies |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE452065B (sv) * | 1986-04-11 | 1987-11-09 | Ulf R Nilsson | Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| AU2001261103B2 (en) * | 2000-04-29 | 2007-08-23 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| US7838165B2 (en) * | 2004-07-02 | 2010-11-23 | Kabushiki Kaisha Toshiba | Carbon fiber synthesizing catalyst and method of making thereof |
| US20090004183A1 (en) * | 2004-07-23 | 2009-01-01 | Taylor Ronald P | Compositions and Methods for Regulating the Alternative Pathway of Complement |
| JP2008521870A (ja) * | 2004-12-02 | 2008-06-26 | ドマンティス リミテッド | 抗ｉｌ−１ｒ１単一ドメイン抗体および治療使用 |
| NZ566915A (en) * | 2005-10-12 | 2011-09-30 | Morphosys Ag | Generation and profiling of human derived therapeutic antibodies specific for human CD38 |
| GB0613209D0 (en) * | 2006-07-03 | 2006-08-09 | Ucb Sa | Methods |
| US8192742B2 (en) * | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
| MX2009013082A (es) * | 2007-06-07 | 2010-01-15 | Genentech Inc | Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento. |
| AR069130A1 (es) * | 2007-11-02 | 2009-12-30 | Novartis Ag | Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento |
-
2010
- 2010-05-04 US US12/773,246 patent/US20100291106A1/en not_active Abandoned
- 2010-05-05 JP JP2012509035A patent/JP2012525829A/ja active Pending
- 2010-05-05 CA CA2760757A patent/CA2760757A1/en not_active Abandoned
- 2010-05-05 EA EA201101593A patent/EA201101593A1/ru unknown
- 2010-05-05 AR ARP100101527A patent/AR076655A1/es not_active Application Discontinuation
- 2010-05-05 CN CN201080026538XA patent/CN102459334A/zh active Pending
- 2010-05-05 MA MA34415A patent/MA33402B1/fr unknown
- 2010-05-05 WO PCT/EP2010/056129 patent/WO2010136311A2/en not_active Ceased
- 2010-05-05 AU AU2010252156A patent/AU2010252156A1/en not_active Abandoned
- 2010-05-05 PE PE2011001908A patent/PE20120899A1/es not_active Application Discontinuation
- 2010-05-05 KR KR1020117029046A patent/KR20120088551A/ko not_active Withdrawn
- 2010-05-05 SG SG2011080330A patent/SG175432A1/en unknown
- 2010-05-05 MX MX2011011754A patent/MX2011011754A/es not_active Application Discontinuation
- 2010-05-05 EP EP10747599A patent/EP2427491A2/en not_active Withdrawn
- 2010-05-05 TW TW099114417A patent/TW201043638A/zh unknown
- 2010-05-06 UY UY0001032612A patent/UY32612A/es not_active Application Discontinuation
-
2011
- 2011-10-14 ZA ZA2011/07551A patent/ZA201107551B/en unknown
- 2011-10-19 TN TNP2011000528A patent/TN2011000528A1/en unknown
- 2011-10-31 IL IL216061A patent/IL216061A0/en unknown
- 2011-11-04 CO CO11150255A patent/CO6440515A2/es not_active Application Discontinuation
- 2011-11-04 CL CL2011002756A patent/CL2011002756A1/es unknown
- 2011-11-08 EC EC2011011445A patent/ECSP11011445A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201101593A1 (ru) | 2012-06-29 |
| US20100291106A1 (en) | 2010-11-18 |
| CL2011002756A1 (es) | 2012-03-23 |
| CN102459334A (zh) | 2012-05-16 |
| TN2011000528A1 (en) | 2013-05-24 |
| AU2010252156A1 (en) | 2011-11-10 |
| TW201043638A (en) | 2010-12-16 |
| EP2427491A2 (en) | 2012-03-14 |
| CA2760757A1 (en) | 2010-12-02 |
| SG175432A1 (en) | 2011-12-29 |
| ECSP11011445A (es) | 2012-01-31 |
| MA33402B1 (fr) | 2012-07-03 |
| WO2010136311A3 (en) | 2011-05-26 |
| JP2012525829A (ja) | 2012-10-25 |
| UY32612A (es) | 2010-12-31 |
| CO6440515A2 (es) | 2012-05-15 |
| KR20120088551A (ko) | 2012-08-08 |
| IL216061A0 (en) | 2012-01-31 |
| ZA201107551B (en) | 2012-07-25 |
| PE20120899A1 (es) | 2012-08-03 |
| WO2010136311A2 (en) | 2010-12-02 |
| MX2011011754A (es) | 2011-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076655A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| CO7250445A2 (es) | Proteínas de unión a antígeno st2 | |
| CO6351748A2 (es) | Anticuerpos contra il-6 y sus usos | |
| UY33703A (es) | Anticuerpos anti-il-23 | |
| BR112013021562A2 (pt) | anticorpos para cd70 | |
| EA201400579A1 (ru) | Антитела к il-36r | |
| CR20160206A (es) | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5 | |
| MX357678B (es) | Moléculas de unión específica a proteína de unión a adn de respuesta transactiva de 43 kda (tdp-43). | |
| BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
| EA201790757A1 (ru) | Связывающие антиген cd27l белки | |
| CR20110358A (es) | Proteinas de enlace de miostatina | |
| CR20130128A (es) | Nuevas proteínas de unión a antígenos | |
| CO6290772A2 (es) | Anticuerpos dirigidos a angiopoietina 1 y angiopoietina 2 y usos de los mismos | |
| MX2013013832A (es) | Proteínas de unión receptoras fc. | |
| CR20120210A (es) | Proteínas de enlace al antigeno il-23 humanas | |
| BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
| AR090923A1 (es) | Anticuerpos anti-il-23 | |
| CL2011002482A1 (es) | Anticuerpo biespecificos que se une especificamente a las proteinas erbb-3 humana y c-met humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar cancer | |
| CR20170262A (es) | Composiciones y métodos para anticuerpos dirigidos a bmp6 | |
| MX2015003150A (es) | Anticuerpos específicos de polipeptido amiloide de islote humano (hiapp) y sus usos. | |
| EA201500502A1 (ru) | Связывающие антиген her3 белки, связывающиеся с бета-шпилькой her3 | |
| AR123070A2 (es) | Anticuerpos anti-il-23 | |
| AR118080A2 (es) | Proteínas de unión a antígeno dirigidas contra el receptor | |
| AR124605A2 (es) | Anticuerpos anti-il-36r | |
| TH150801A (th) | แอนติ-HER แอนติบอดี้ที่จำเพาะ 2 ตำแหน่ง (Bispecific Anti-HER Antibodies) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |